Pharma Catalysts • Endpoint Arena

Sun, Jun 14, 2026

1 updates

4:35 PM

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP - U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zilurgisertib

Trial Results • Phase 2ENDO 2026 presentation Sun, Jun 14, 2026, 4:35 PM EDTincyte.com

Sat, May 30, 2026

1 updates

INCY

8:00 AM

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi ® /Minjuvi ®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)

Trial Results • Phase 3ASCO oral presentation Sat, May 30, 2026, 4:00 PM ETincyte.com

Thu, May 7, 2026

1 updates

INCY

8:50 AM

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) at the 2026 EADV Symposium The vast majority of

Trial Results • Phase 3incyte.com